U.S. markets open in 9 hours 17 minutes

IRIDEX Corporation (IRIX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.4700-0.1000 (-3.89%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close2.5700
Bid2.0500 x 1000
Ask2.9500 x 1000
Day's Range2.4700 - 2.6600
52 Week Range2.4700 - 9.4600
Avg. Volume41,020
Market Cap39.241M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.3550
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IRIX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • IRIDEX Corporation
    LMAT: Raising target price to $48.00LEMAITRE VASCULAR INC has an Investment Rating of HOLD; a target price of $48.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Iridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China

    MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced that it has received regulatory clearance to market and sell its Cyclo G6® platform for the treatment of glaucoma diseases in China by its National Medical Products Administration (NMPA). In accordance with the clearance, Iridex and distribution partners Topcon and Clinico w

  • Zacks

    Iridex (IRIX) Reports Q1 Loss, Misses Revenue Estimates

    Iridex (IRIX) delivered earnings and revenue surprises of 6.25% and 0.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Iridex Announces First Quarter 2022 Financial Results

    Achieved Record First Quarter RevenueMOUNTAIN VIEW, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2, 2022. First Quarter 2022 Highlights Record first quarter revenue of $13.4 million, an increase of 12% from the prior year periodCyclo G6® product family revenue of $3.5 million, an increase of 6% year-over-year 14,700 Cyclo G6 probes sold, an 8% increase year-over-year56 Cyclo G6 Glaucoma Laser Systems